Teva and Mylan are continuing to press their takeover bids in an increasingly hostile M&A chain, while Perrigo remains staunch in its defence. Ireland-based Perrigo has just rejected Mylan's third ...

Mylan’s long-awaited rival for Teva’s blockbuster multiple sclerosis drug Copaxone has been approved in the US, putting a large chunk of the Israeli firm’s revenues at risk. The timing could ...

In 2020 it won a ruling that Teva’s product patent was invalid, and it was thus revoked across Europe. At the time, Synthon ...

In April 2014, after the drugmaker Mylan hiked prices on more than seven of its drugs, Teva Pharmaceutical Industries, the world's largest generic drugmaker and one of Mylan's biggest rivals ...

Wednesday, Teva revealed booming third-quarter sales for its generics and biosimilars. In the U.S., revenue from the knockoffs came in at $1.1 billion, which was a 30% increase year over year, or ...

In the largest settlement of its kind, Teva Pharmaceuticals agreed to pay $425 million to resolve allegations the company and a related business paid kickbacks to charitable foundations in order ...

DelveInsight’s “Post Bariatric Hypoglycemia Market Insights, Epidemiology, and Market Forecast – 2034” report delivers an ...

JERUSALEM, Nov 6 (Reuters) - Teva Pharmaceutical Industries (TEVA.TA), opens new tab raised its 2024 revenue and earnings guidance on Wednesday after beating third-quarter profit forecasts ...

11 October 2022 European Commission says pharma firm blocked generics over blockbuster MS drug| Teva “engaged in abusive conduct” to “artificially prolong the exclusivity” of Copaxone | Teva could be ...

Teva gets a buy rating as it trades well below 10-year highs and shows growth potential as the leading global generic drugmaker. Their drug pipeline is robust and diverse, as well as existing ...

BOSTON (Reuters) - Teva Pharmaceutical Industries Ltd (TEV.SG) has agreed to pay $450 million to resolve allegations it used charities that help cover Medicare patients' out-of-pocket drug costs ...

Teva Pharmaceuticals Industries Ltd (NYSE:TEVA) has agreed to a $450 million settlement with the U.S. government to resolve allegations that they violated the Anti-Kickback Statute (AKS) and the ...